NCT03578185Recruiting
Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy
Source: ClinicalTrials.gov · Last updated 12 Aug 2026
Brief summary (registry, in English)
This study is designed to identify the predictive biomarker for immunotherapy using patient samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 25 Jun 2018
- Start date
- 11 Apr 2018
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- Samsung Medical Center
- Diseases
- Lung cancer
- NCT number
- NCT03578185
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 11 Apr 2018 to the primary completion date, 31 Dec 2030
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- aged above or equal to 18
- Histologically confirmed lung cancer patients
- Patient treated with immune checkpoint inhibitor
- Exculsion Criteria:
- NA
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Asan Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Not yet recruiting |
| Seoul National University Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.